UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1689-1699

2015

Volltextzugriff (PDF)

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Clinical cancer research, 2019-09, Vol.25 (18), p.5485-5492

2019

Volltextzugriff (PDF)

The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning

Biomolecules (Basel, Switzerland), 2020-07, Vol.10 (8), p.1123

2020

Volltextzugriff (PDF)

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Volltextzugriff (PDF)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Japanese journal of clinical oncology, 2019-01, Vol.49 (1), p.29-36

2019

Volltextzugriff (PDF)

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Cancer science, 2018-11, Vol.109 (11), p.3583-3590

2018

Volltextzugriff (PDF)

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Volltextzugriff (PDF)

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

European journal of cancer (1990), 2019-05, Vol.113, p.78-86

2019

Volltextzugriff (PDF)

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Cancer science, 2022-12, Vol.113 (12), p.4300-4310

2022

Volltextzugriff (PDF)

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

Lung cancer (Amsterdam, Netherlands), 2015-05, Vol.88 (2), p.154-159

2015

Volltextzugriff (PDF)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-02, Vol.14 (1), p.1070-1070, Article 1070

2023

Volltextzugriff (PDF)

Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient

Japanese journal of clinical oncology, 2019-08, Vol.49 (8), p.793-794

2019

Volltextzugriff (PDF)

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

Japanese journal of clinical oncology, 2020-05, Vol.50 (5), p.502-511

2020

Volltextzugriff (PDF)

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

The lancet oncology, 2013-06, Vol.14 (7), p.590-598

2013

Volltextzugriff (PDF)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Scientific reports, 2021-09, Vol.11 (1), p.18762-18762, Article 18762

2021

Volltextzugriff (PDF)

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2018-10, Vol.124, p.179-188

2018

Volltextzugriff (PDF)

CD20+ tumor‐infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma

Cancer science, 2020-06, Vol.111 (6), p.1921-1932

2020

Volltextzugriff (PDF)

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

The lancet respiratory medicine, 2017-01, Vol.5 (1), p.42-50

2017

Volltextzugriff (PDF)

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

The New England journal of medicine, 2009-09, Vol.361 (10), p.947-957

2009

Volltextzugriff (PDF)

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression

Clinical cancer research, 2021-03, Vol.27 (5), p.1410-1420

2021

Volltextzugriff (PDF)

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Cancer Immunology, Immunotherapy, 2020-01, Vol.69 (1), p.15-22

2020

Volltextzugriff (PDF)

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1114-1122

2021

Volltextzugriff (PDF)

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

PloS one, 2014-07, Vol.9 (7), p.e102436

2014

Volltextzugriff (PDF)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance

Cancer science, 2021-11, Vol.112 (11), p.4692-4701

2021

Volltextzugriff (PDF)

Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions: A propensity score analysis

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.220-228

2023

Volltextzugriff (PDF)

1 – 25 von 726

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Chemotherapy And Pharmacology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(650)
Mit Volltextzugriff
(685)

Publikationsform

Sprache

Englisch
(683)
Japanisch
(165)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(420)
Life Sciences & Biomedicine
(411)
Oncology
(366)
Humans
(341)
Female
(239)
Male
(237)
Aged
(226)
Middle Aged
(214)
Lung Neoplasms - Drug Therapy
(205)
Adult
(171)
Lung Cancer
(154)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(153)
Lung Neoplasms - Pathology
(114)
Chemotherapy
(107)
Respiratory System
(105)
Aged, 80 And Over
(96)
Retrospective Studies
(84)
Non-Small Cell Lung Cancer
(82)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(80)
Tumors
(79)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(102)
Japanese Journal Of Clinical Oncology
(69)
Lung Cancer
(51)
Journal Of Thoracic Oncology
(44)
Cancer Science
(41)
Annals Of Oncology
(40)
Japanese Journal Of Lung Cancer
(20)
Cancer Research
(16)
Clinical Lung Cancer
(15)
Japanese Journal Of Cancer Research
(14)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

CD20+ tumor‐infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance

Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions: A propensity score analysis

Aktive Filter

Suchergebnisse filtern